The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Open accessAbstract
A syndrome similar to idiopathic parkinsonism developed after intravenous self-administration of an illicit drug preparation in which N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) might have been responsible for the toxicity. In the present study we show that intravenous administration of NMPTP to the rhesus monkey produces a disorder like parkinsonism (akinesia, rigidity, postural tremor, flexed posture, eyelid closure, drooling) that is reversed by the administration of L-dopa. NMPTP treatment decreases the release of dopamine and dopamine accumulates in swollen, distorted axons in the nigrostriatal pathway just above the substantia nigra, followed by severe nerve cell loss in the pars compacta of the substantia nigra and a marked reduction in the dopamine content of the striatum. The pathological and biochemical changes produced by NMPTP are similar to the well-established changes in patients with parkinsonism. Thus, the NMPTP-treated monkey provides a model that can be used to examine mechanisms and explore therapies of parkinsonism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Aromatic Amino Acids and Modification of Parkinsonism
Cotzias, G. C., Van Woert, M. H., & Schiffer, L. M. (1967) · New England Journal of Medicine · doi:10.1056/nejm196702162760703 · Cited by 1,494
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Self-citationCatecholamine metabolism in the brains of ageing male mice
Finch, C. E. (1973) · Brain Research · doi:10.1016/0006-8993(73)90663-x · Cited by 345
An ambulatory activity monitor with solid state memory.
Colburn, T. R., Bm, S., Jj, G., & Nn, S. (1976) · PubMed · Cited by 103
Gordon, E. K., Oliver, J., Black, K., & Kopin, I. J. (1974) · Biochemical Medicine · doi:10.1016/0006-2944(74)90092-1 · Cited by 83
Self-citationBromocriptine treatment in Parkinson's disease.
Parkes, J. D., MARSDEN, C. D., Donaldson, I. M., et al. (1976) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.39.2.184 · Cited by 76
Jimerson, D. C., Markey, S. P., Oliver, J., & Kopin, I. J. (1981) · Journal of Mass Spectrometry · doi:10.1002/bms.1200080606 · Cited by 68
Self-citation
Cited by
Items 101–128 of 128
Calabrese, V., Cornelius, C., Mancuso, C., Pennisi, G., Calafato, S., Bellia, F., Bates, T. E., Giuffrida Stella, A. M., Schapira, T., Dinkova Kostova, A. T., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9775-9 · Cited by 268
Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease
Martinez, T. N., & Greenamyre, J. T. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4033 · Cited by 266
Cassarino, D. S., Fall, C. P., Swerdlow, R. H., Smith, T. S., Halvorsen, E. M., Miller, S. W., Parks, J. P., Parker, W. D., & Bennett, J. P. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(97)00070-7 · Cited by 265
Yokota, T., Igarashi, K., Uchihara, T., Jishage, K.-I., Tomita, H., Inaba, A., Li, Y., Arita, M., Suzuki, H., Mizusawa, H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261456098 · Cited by 261
Sriram, K., Benkovic, S. A., Hebert, M. A., Miller, D. B., & O'Callaghan, J. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309304200 · Cited by 261
The role of the locus coeruleus in the development of Parkinson's disease
Gesi, M., Soldani, P., Giorgi, F. S., Santinami, A., Bonaccorsi, I., & Fornai, F. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00028-2 · Cited by 258
Neurodegeneration and neuroprotection in Parkinson disease
Fahn, S., & Sulzer, D. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.139 · Cited by 257
Pathophysiology of Parkinson's Disease: The MPTP Primate Model of the Human Disorder
WICHMANN, T., & DeLONG, M. R. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07477.x · Cited by 255
Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis
Banerjee, R., Starkov, A. A., Beal, M. F., & Thomas, B. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.11.007 · Cited by 253
Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., & Kopin, I. J. (1985) · New England Journal of Medicine · doi:10.1056/nejm198505303122203 · Cited by 244
Self-citationParkinson’s disease as a result of aging
Rodriguez, M., Rodriguez‐Sabate, C., Morales, I., Sanchez, A., & Sabate, M. (2015) · Aging Cell · doi:10.1111/acel.12312 · Cited by 214
Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N. (1995) · Neurosurgery · doi:10.1227/00006123-199510000-00018 · Cited by 134
Crossman, A. R., Mitchell, I. J., & Sambrook, M. A. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90070-x · Cited by 121
Sleep Disturbances in Alzheimer’s and Parkinson’s Diseases
Rothman, S. M., & Mattson, M. P. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8181-2 · Cited by 102
Singer, T. P., Ramsay, R. R., McKeown, K., Trevor, A., & Castagnoli, N. E. (1988) · Toxicology · doi:10.1016/0300-483x(88)90169-2 · Cited by 96
Ugalde, C. L., Finkelstein, D. I., Lawson, V. A., & Hill, A. F. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13772 · Cited by 92
Fuentes, R., Petersson, P., & Nicolelis, M. A. L. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07417.x · Cited by 85
Martinovits, G., Melamed, E., Cohen, O., Rosenthal, J., & Uzzan, A. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90602-6 · Cited by 67
Circadian dysregulation in Parkinson's disease
Videnovic, A., & Golombek, D. (2017) · Neurobiology of Sleep and Circadian Rhythms · doi:10.1016/j.nbscr.2016.11.001 · Cited by 63
“The latter induces motor symptoms accompanied by a specific loss of dopaminergic neurons (Burns et al., 1983).”
BackgroundShang, T., Kotamraju, S., Kalivendi, S. V., Hillard, C. J., & Kalyanaraman, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400101200 · Cited by 62
Stimulation on Demand: Closing the Loop on Deep Brain Stimulation
Santos, F. J., Costa, R. M., & Tecuapetla, F. (2011) · Neuron · doi:10.1016/j.neuron.2011.10.004 · Cited by 60
Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates
Bodis-Wollner, I., Chung, E., Ghilardi, M. F., Glover, A., Onofrj, M., Pasik, P., & Samson, Y. (1991) · Journal of Neural Transmission - Parkinson's Disease and Dementia Section · doi:10.1007/bf02251137 · Cited by 51
Iron-mediated bioactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in glial cultures
Di Monte, D. A., Schipper, H. M., Hetts, S., & Langston, J. W. (1995) · Glia · doi:10.1002/glia.440150213 · Cited by 43
Masilamoni, G. J., Groover, O., & Smith, Y. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.025 · Cited by 37
“…al., 1993), most likely due to differences in the type of toxins used, their regimen of administration, and the rigor with which quantitative methods were applied to assess these changes (Burns et al., 1983; Langston et al., 1984; Mitchell et al., 1985; Snyder and D’Amato, 1986; Gibb et al., 1989).”
MethodTam, S. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8012 · Cited by 34
Hineno, T., Mizobuchi, M., Hiratani, K., Inami, Y., & Kakimoto, Y. (1992) · Brain Research · doi:10.1016/0006-8993(92)90930-8 · Cited by 34
Fifel, K., Piggins, H., & Deboer, T. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.02.005 · Cited by 30
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Metadata
- Authors
- Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1983-07
- Volume
- 80
- Issue
- 14
- Pages
- 4546-4550
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2169622817
- Cited by
- 2,149
- References
- 9
- FWCI
- 87.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.